Validation of the Cepheid GeneXpert for Detecting Ebola Virus in Semen by Loftis, Amy James et al.
The Journal of Infectious Diseases
344 • JID 2017:215 (1 February) • Loftis  et al
Validation of the Cepheid GeneXpert for Detecting Ebola 
Virus in Semen
Amy James Loftis,1 Saturday Quellie,3 Kelly Chason,2 Emmanuel Sumo,3 Mason Toukolon,3 Yonnie Otieno,4 Heinzfried Ellerbrok,5 Marcia M. Hobbs,1 
David Hoover,4 Karine Dube,4 David A. Wohl,1,a and William A. Fischer II2,a
1Division of Infectious Diseases, University of North Carolina, Chapel Hill; 2Division of Pulmonary and Critical Care Medicine, University of North Carolina, Chapel Hill; 3Phebe 
Hospital PCR Laboratory, Suokoko, Bong County, Liberia; 4Clinical Research Management, Africa, Hinckley, Ohio; 5Robert Koch Institute, Berlin, Germany
Background. Ebola virus (EBOV) RNA persistence in semen, reported sexual transmission, and sporadic clusters at the end of 
the 2013–2016 epidemic have prompted recommendations that male survivors refrain from unprotected sex unless their semen is 
confirmed to be EBOV free. However, there is no fully validated assay for EBOV detection in fluids other than blood.
Methods. The Cepheid Xpert Ebola assay for EBOV RNA detection was validated for whole semen and blood using samples 
obtained from uninfected donors and spiked with inactivated EBOV. The validation procedure incorporated standards from Clinical 
and Laboratory Standards Institute and Good Clinical Laboratory Practices guidelines for evaluating molecular devices for use in 
infectious disease testing.
Results. The assay produced limits of detection of 1000 copies/mL in semen and 275 copies/mL in blood. Limits of detection 
for both semen and blood increased with longer intervals between collection and testing, with acceptable results obtained up to 72 
hours after specimen collection.
Conclusions. The Cepheid Xpert Ebola assay is accurate and precise for detecting EBOV in whole semen. A validated assay for 
EBOV RNA detection in semen informs the care of male survivors of Ebola, as well as recommendations for public health.
Keywords.  Ebola; Semen; Validation; Cepheid Xpert.
During the recent outbreak of Ebola virus (EBOV) in West 
Africa, assays to detect the virus in blood were readily estab-
lished, allowing healthcare providers to identify infected indi-
viduals, facilitate their admission to Ebola treatment units and 
mitigate ongoing community transmission through their treat-
ment and isolation. Throughout the epidemic, the US Food and 
Drug Administration authorized the emergency use of in vitro 
diagnostics for EBOV detection, but these diagnostics were 
limited to testing of whole-blood or buccal swab samples [1].
Reports of Ebola viral RNA detected in semen of EBOV 
disease (EVD) survivors and at least 1 case of documented 
sexual transmission of the virus has led to interest in detect-
ing EBOV in other body fluids, particularly genital secretions. 
Findings from a study led by the Centers for Disease Control 
and Prevention, the World Health Organization (WHO), and 
the Liberian Ministry of Health suggest that the prevalence of 
viral persistence and shedding in semen may be as high as 26% 
among men 7–9  months after recovery from acute EVD [2]. 
A case of recrudescent EBOV in the cerebrospinal fluid of an 
EVD survivor and prior reports of detection of the viral RNA in 
breast milk expand the list of fluids for which detection of the 
virus is needed [3, 4].
Concerns for the sexual transmission of EBOV has led to 
recommendations by the WHO that men refrain from unpro-
tected sexual intercourse for at ≥12 months after EVD recovery 
or until their semen is confirmed to be EBOV free [5]. However, 
despite this recommendation and the need for accurate testing 
for EBOV in this and other body fluids, no fully validated assay 
is available for EBOV detection in fluids other than blood.
We report results of the first clinical validation of a poly-
merase chain reaction (PCR) assay for EBOV in semen. Given 
the safety concerns of handling specimens potentially infected 
with a high-consequence pathogen, the Cepheid GeneXpert 
PCR platform was selected because RNA isolation, amplifica-
tion, and detection are contained, and the assay does not require 
repeat manipulation of the specimen—all features that lead to 
increased operator safety.
METHODS
Setting
Assay validation was performed at the Phebe Hospital PCR 
Laboratory in Bong County, Liberia. The laboratory layout fol-
lows recommendations from the Centers for Disease Control 
and Prevention and WHO [6–10]. Briefly, the laboratory is sep-
arated into high- and low-risk areas. The high-risk area con-
tains an area to don and doff personal protective equipment, an 
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area for sample reception and decontamination, and an area for 
specimen preparation and virus inactivation within a glove box. 
The low-risk area contains separate pre- and postamplification 
rooms.
Assay Platform
The Cepheid Xpert Ebola assay is a rapid, automated test for 
qualitative detection of the Ebola Zaire virus on the Cepheid 
GeneXpert Instrument System. The GeneXpert system allows 
automated extraction and quantitative real-time reverse-tran-
scription (RT) PCR. The Xpert Ebola assay detects EBOV total 
nucleic acid, amplifying the glycoprotein (GP) and nucleopro-
tein (NP) genes. Each test cartridge includes a sample adequacy 
control to ensure that human cells are present in the sample; a 
Cepheid internal control, an Armored RNA dry bead included 
in each cartridge to verify adequate lysing of the sample virus 
and monitor for the presence of inhibitors; and a probe check 
control to ensure bead rehydration, reaction-tube filling, 
probe integrity, and dye stability that occurs before RT-PCR 
[11–14]. This test was granted an emergency use authori-
zation from the US Food and Drug Administration on 23 
March 2015.
Samples
The validation procedure was designed to incorporate stan-
dards from Clinical and Laboratory Standards Institute and 
Good Clinical Laboratory Practices guidelines for evaluating 
molecular devices for use in infectious disease testing [15–21]. 
For the verification of blood and the validation of semen test-
ing, samples of both body fluids were collected from uninfected 
individuals and spiked with reconstituted lyophilized EBOV. 
The lyophilized EBOV stock (donated by Heinzfried Ellerbrok 
of the Robert Koch Institute, Hamburg, Germany, and origi-
nally provided by Stephan Günther from the Bernhard Nocht 
Institute for Tropical Medicine in Hamburg) originated from 
a Gueckedou isolate of the Ebola Zaire strain. The virus stock 
was heat-inactivated and subsequently gamma-irradiated, and 
the absence of infectivity was confirmed by cultivation exper-
iments. The nucleic acid content of the heat-inactivated and 
gamma-irradiated virus stock was verified by 3 expert Ebola 
testing laboratories (personal communication, Heinz Ellerbrok, 
manuscript in preparation). 
Virus stock was diluted by genomic equivalents in the send-
ing laboratory. For our work, the lyophilized EBOV samples 
were reconstituted with 100  μL of Molecular Grade RNase-, 
DNase- and protease-free water (Corning), and serial dilutions 
were prepared using the donor specimens. Aliquots of spiked 
samples were prepared and tested over 3 days, then a new vial 
of lyophilized virus was reconstituted and samples were pre-
pared for use over the next 3 days. This procedure was repeated 
until all testing was completed. Testing of all validation samples 
occurred within 72 hours after collection to evaluate stability of 
the gene targets (GP and NP) and sample integrity for each sam-
ple type. Statistical and logistical factors were considered when 
determining acceptable stability limits; limits were defined as 
acceptable if the probit analysis of analytical limits of detection 
on day 3 shows results within ±0.25 log10 copies/mL of those 
achieved on day 1.
Blood
Because EBOV RNA detection in blood has previously been val-
idated using the Cepheid GeneXpert PCR platform, sensitivity 
and repeatability were verified by testing 40 EBOV-spiked posi-
tive and 20 negative donor samples on each instrument in local 
conditions [22–26]. Blood was collected in two 4-mL EDTA 
tubes from 4 donors, was spiked immediately after collection 
with the reconstituted virus stock to achieve a dilution series of 
samples containing 102–106 copies/mL, and was aliquoted into 
multiple sets of complete dilution series that consisted of 5 con-
centrations run in singlet over 4 days (n = 20) to show repeat-
ability and 2 concentrations run in duplicate (n = 16) to verify 
sensitivity and repeatability experiments over the same 4 days. 
The negative (undiluted) donor samples were run 5 times each 
day (total n = 20). The first set of the dilution series samples was 
tested the same day as collection and spiking; the remaining sets 
were stored at 2°C–8°C until testing.
Semen
The validation of EBOV RNA detection in semen was then 
performed using 150 spiked samples and 25 negative samples 
tested on each instrument (n = 300 and n = 50, respectively). 
Semen was collected in 3-oz 88.72 mL sterile collection cups 
from 6 donors. Panels of logarithmic dilutions were prepared to 
test in triplicate for 5 days to show repeatability (n = 30 for each 
concentration), and 3 concentrations were tested in duplicate 
for 15 days to establish sensitivity and further confirm repeat-
ability (n = 70 for each concentration). Semen was allowed to 
liquefy for 30–45 minutes before spiking with the EBOV stock 
in the same manner used for blood, the first set of the dilution 
series was tested on the day that spiking was completed, and the 
remaining sets were stored at 2°C–8°C until testing.
Assay
All tests were performed using a single Xpert Ebola Test lot 
across all days of testing. Samples were tested on 2 GeneXpert 
Instruments, and testing was rotated between 2 technicians 
each day. Concordance between the 2 GeneXpert instruments 
was verified by testing a WHO Proficiency Panel II (provided 
by the Robert Koch Institute) consisting of 11 blinded samples. 
The lyophilized proficiency panel samples were reconstituted 
with 100 μL of Corning Molecular Grade RNase-, DNase- and 
Protease-free Water, and the entire reconstituted volume was 
processed and tested according the manufacturer’s package 
insert [11]. Briefly, 100 μL of sample was added to the kit lysis 
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buffer. After a 10-minute incubation period at ambient tem-
perature (15°C–28°C), 1000 μL of sample/lysis buffer was added 
to the Xpert Ebola Cartridge and loaded onto the GeneXpert 
module for testing. 
Blood samples were processed and tested per the manu-
facturer’s package insert, and semen samples (100  μL) were 
also processed and tested in the same manner as blood, 
with 1 additional step. After the initial incubation period, 
each semen sample was treated with 100 μL of the reducing 
agent, dithiothreitol (1  mol/L; Sigma-Aldrich) for an addi-
tional incubation of 10 minutes at ambient temperature 
(15°C–28°C) to reduce viscosity. Test results were interpreted 
by the GeneXpert Dx System from measured fluorescence sig-
nals based on algorithms embedded within the assay software 
[11]. Samples are considered positive if either target gene (GP 
or NP) was detected; the instrument identifies which targets 
are detected.
Controls
A set of commercial controls, the SeraCare Ebola Control 
Bundle, was obtained from Cepheid [27]. One positive control 
(rEbolaGP-NP, containing both gene targets) and 1 negative 
control (human serum) from the bundle was tested each day 
that testing occurred and cycle threshold (Ct) values of the con-
trols were plotted as part of the quality control and assurance 
for stability of the instrument and test. The semen extraction 
controls consisted of negative donor semen (undiluted), tested 
in triplicate over 5 days and in singlet over an additional 10 days 
on each instrument (n = 50); the EBOV-spiked samples with 
nominal concentrations of 106 copies/mL were used as positive 
controls to validate the inactivation procedure, tested in singlet 
over the 15 days on each instrument (n = 30).
Specimen Biosafety Procedure
The specimen biosafety protocol for Ebola samples consists of 
a thorough decontamination of the primary sample container 
(cooler box), secondary container (specimen bag), specimen 
and paperwork by spraying with 0.5% sodium hypochlorite 
solution (10% bleach) prepared fresh weekly. Contact time was 
≥10 minutes for each step. Once the sample was decontam-
inated, entered into the laboratory specimen log, and given a 
laboratory-specific identification number, it was placed into 
the glove box and prepared for PCR testing. For the GeneXpert 
Ebola test, 100 µL of semen was added to the lysis buffer and 
incubated for 10 minutes. The inactivated sample was then 
wiped with an alcohol wipe (70% ethanol) and passed through 
the exit chamber where it underwent another 10% bleach 
cleansing step (10 minutes of contact time). This decontami-
nation procedure was performed wearing appropriate personal 
protective equipment, which consisted of a powered purified air 
respirator or N95 mask, an impermeable Tyvek suit and boot 
covers, triple gloves, a head cover, and a shield).
Statistical Analysis
The GeneXpert software will not generate target Ct values when 
a test is valid but the targets are not detected. All instrument 
Ct values were entered into MS Excel for Mac and proportions 
and 95% confidence intervals were estimated using VassarStats: 
Website for Statistical Computation (Vassar College). Multiple 
logistic regression analyses were conducted using SigmaStat in 
SignaPlot version 13 for Windows (Systat Software) to deter-
mine the likelihood of a positive test over a range of nominal 
EBOV concentrations in blood and semen.
RESULTS
Analytical Sensitivity and Repeatability in Semen and Blood
The GeneXpert instrument uses the internal control and tar-
get gene Ct values to determine whether the assay is valid and 
which of the targets (GP, NP, or both) is detected [11]. Validation 
of blood was undertaken to allow for a direct comparison of 
the performance of the assay in detecting EBOV RNA in each 
of these fluids. On both instruments, the assay detected GP 
and/or NP for all concentrations for both sample types, with 
the exception of the 100 copies/mL (0 of 8 detected) that was 
tested for blood only. The analytical sensitivity and repeatability 
results for whole blood and semen are shown in Table 1. There 
was no discernible difference between the 2 instruments for 
repeatability and analytical sensitivity; therefore, all data points 
are combined for all analyses, with the exception of the direct 
instrument correlation data.
The analytical limit of detection (LOD) was estimated as the 
concentration corresponding to a 95% probability of a positive 
test result for each specimen tested on days 1 and 3 after spiking 
with dilutions of inactivated virus stock (Figure 1) [28]. In pro-
bit analysis, the 95% LOD for blood was 275 copies/mL (2.44 
log copies/mL) on day 1 and 279 copies/mL (2.45 log copies/
mL) on day 3. Probit analysis for semen showed that the 95% 
LOD was 1000 copies/mL (3.00 log copies/mL) on day 1 and 
1259 copies/mL (3.10 log copies/mL) on day 3. Unspiked blood 
and semen donor samples (n = 40 and n = 50, respectively) 
were all undetected (Table 1).
Detectability With Increasing Time From Specimen Collection to Testing
Target detectability, in whole blood and semen, was determined 
by testing the EBOV-spiked samples on days 1, 2, and 3 (up 
to 72 hours after collection), and stability was determined by 
the presence of either gene target. At least 1 of the target genes 
(GP or NP) was detectable over all 3 days for all concentration 
replicates down to 1000 EBOV-spiked copies/mL. The NP gene 
was detected for all but 1 replicate of the 500 EBOV-spiked 
copies /mL in blood samples (15 of 16); for semen samples, 
NP was detected in 46 of 70 samples with 500 EBOV-spiked 
copies/mL. The 250 EBOV-spiked copies /mL sample repli-
cate results showed a decrease in detectability for both sample 
types (Table  2). For blood, there is a slight decrease in target 
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detectability over 72 hours at the LOD, although the predicted 
difference in LOD of −0.01 log copies/mL was within ±0.25 log 
copies/mL. Similarly, for semen, the predicted difference in 
LOD was −0.10 log copies/mL, also within the acceptable range.
There was an observed difference in target gene detectability 
in both sample types for testing completed over the entire study. 
The NP gene was detected in 84% (95% confidence interval, 
74%–91%) of blood samples (54 of 64) and 77% ( 72%−81%) 
of semen samples (231 of 300), and the GP gene was detected 
in 47% (35%−59%) of blood samples (30 of 64)  and 51% 
(45%−56%) of semen samples (152 of 300).
Instrument Concordance and Biosafety Procedure Validation
The WHO proficiency panel consisted of 11 blinded samples. The 
EBOV samples were detected, whereas while Marburg virus and 
negative samples were not detected on both instruments (Table 3).
The commercial controls were tested each day throughout 
the duration of the validation study on each instrument. The 
Ct values were plotted as part of quality control and assurance 
for stability of the instrument and test for each target, GP and 
NP, for the positive control (Figure 2). All positive and negative 
controls were valid, and there were no false-positives (negative 
controls with positive results) or false-negatives (positive con-
trols with negative results) for either instrument (Table 1).
Validation of the specimen biosafety procedure was completed, 
using the prepared specimen-specific controls to ensure that 
specimen handling and sample inactivation practices would not 
inhibit PCR and result in false-negatives and also to ensure proper 
handling to minimize contamination resulting in false-positives. 
The semen positive control was spiked to contain 106 copies/mL 
sample, and the negative control was undiluted donor sample. No 
false-negative or false-positive results were observed for either 
instrument (all 30 positive semen controls had positive results, 
compared with 0 of 50 negative semen controls) (Table 1).
Discussion
Diagnostics are critical to emerging infectious diseases response. 
Throughout the 2013–2016 Ebola epidemic, diagnostic molec-
ular-based platforms have been used to triage suspect cases, 
determine discharge eligibility, and, more recently, determine the 
duration of asymptomatic EBOV shedding in the semen of male 
survivors [2, 29–31]. However, interpretation of results from tests 
that have not been validated pose a challenge, because the limits 
of detection and accuracy of these assays under different condi-
tions have not been defined. Given the threat of viral persistence 
in body fluids, including semen, and the recognition of sexual 
contact as a means of transmission of EBOV, a validated test to 
detect the presence of EBOV RNA in semen is essential to deter-
mine the duration of viral shedding and support public health 
recommendations to prevent sexual transmission of this virus.
In this first validation of EBOV PCR testing for semen we 
found the Cepheid Xpert Ebola assay to be accurate, precise 
and stable for detecting EBOV in semen and comparable to the 
testing of whole blood, with limits of detection of approximately 
1000 and 275 copies/mL, respectively. An important finding 
Figure 1. Statistical limits of detection. Solid line represents blood samples on 
day 1; dotted line, blood samples on day 3; dashed line, semen samples on day 1; and 
dashed and dotted line, semen samples on day 3. Abbreviation: EBOV, Ebola virus.
Table 1. Analytical Sensitivity and Repeatability in Whole-Blood and Semen Samples
Blood Semen
Nominal 
Viral RNA 
Copies/mL
Total 
No.
Positive  
Results, No.
% Detected 
(95% CI)
Ct, Mean (SD)
Nominal 
Copies/mL
Total 
No.
Positive  
Results, No.
% Detected 
(95% CI)
Ct, Mean (SD)
GP NP GP NP 
1 000 000 8 8 100 (68–100) 33.9 (0.4) 29.5 (0.4) 1 000 000 30 30 100 (89–100) 36.2 (1.5) 31.7 (1.5)
100 000 8 8 100 (68–100) 37.3 (1.2) 33.1 (1.1) 100 000 30 30 100 (89–100) 37.7 (1.0) 32.9 (0.9)
10 000 8 8 100 (68–100) 39.8 (2.2) 36.3 (2.1) 10 000 30 30 100 (89–100) 40.8 (1.5) 36.1 (1.4)
1000 8 8 100 (68–100) 36.3 (1.2) 36.1 (4.5) 1000 70 66 94 (89–99) 39.2 (3.4) 38.2 (3.6)
500 16 15 94 (72–99)  NA 37.2 (3.6) 500 70 48 69 (57–78) NA NA
250 16 9 56 (33–77) NA NA 250 70 36 51 (40–63) NA NA
100 16 0 0 (0–32) NA NA 0 50 0 0 (0–13) NA NA
0 40 0 0 (0–16) NA NA NA NA NA NA NA NA
Abbreviations: CI, confidence interval; Ct, cycle threshold; GP, glycoprotein; NA, not applicable; NP, nucleoprotein. 
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was the effect of time from collection to testing on assay per-
formance. Based on our data, consistent results for semen and 
whole blood can be achieved when testing is performed within 
72 hours of specimen collection, with only a slight decrease in 
sensitivity (1259 and 279 copies/mL in semen and blood at day 
3, respectively). In addition to the performance of the Cepheid 
Xpert platform in detecting EBOV RNA in semen, the lack of 
false-positive and false-negatives in this fluid also validates the 
specimen biosafety procedure. Quality control is paramount, 
and extraction controls should be tested along with the patient 
samples to assure that accurate results are achieved and reported.
Our findings are concordant with a recent report by Pettit 
and colleagues [32], who compared the performance of a quan-
titative RT-PCR assay for detecting EBOV in blood and semen. 
In contrast to that study, we also completed method validation 
for the Cepheid Xpert system for detecting EBOV RNA in 
semen by defining the limits of detection and reproducibility. 
The Cepheid Xpert system offers a number of advantages over 
standard PCR methods, including incorporation of internal 
controls for host species and virus, rapid processing time, and 
reduced need for specimen handling. That the system was able 
to also perform well in detecting EBOV RNA in semen greatly 
expands its research and clinical utility, given the evidence of 
seminal persistence and sexual transmission of this virus. At 
present, testing of semen for EBOV is largely inaccessible to 
men in West Africa, and the limited testing that is being con-
ducted has not, to our knowledge, been validated for this body 
fluid. Our validation of the Cepheid Xpert Ebola assay removes 
at least one obstacle to its being more widely available to men 
who have recovered from EVD.
However, despite the performance characteristics of the 
Cepheid Xpert for Ebola in semen, much remains unknown 
about the results of this and any other EBOV PCR technique 
in this body fluid. Because the test detects RNA targets, it is 
not clear whether a detectable result indicates the presence of 
infectious virus. Similarly, an undetectable result cannot be 
interpreted to indicate the complete absence of virus or risk of 
infectiousness, because there is no established threshold for the 
concentration of EBOV in the semen below which transmission 
is not possible. Therefore, counseling and clinical decision mak-
ing should incorporate messaging regarding the limitations of 
the assay when it is used.
Our study had several limitations. We were unable to assess 
clinical samples, particularly those with high virus titers that 
would be seen in an outbreak; therefore, additional assess-
ment of the biosafety procedure and complete inactivation of 
live EBOV using the Xpert Ebola assay was not performed. 
The inclusion of commercial controls and extraction controls 
requires a stable environment monitored by trained laboratory 
staff with access to consistent power supply in a space that is 
temperature controlled (for the instrument and reagents), not 
easily implemented in the field during an outbreak. In addition, 
we chose to use precision pipettes for sample inactivation and 
addition to the cartridge; we did not use the swab or Pasteur 
pipettes included in the kit. It is worth noting, however, that 
these instruments are widely used in Africa for tuberculosis 
testing, in various settings, and the Xpert Ebola assay could be 
added to the test menu if needed. 
Importantly, EBOV used for this validation study was first 
heat-inactivated and gamma-irradiated. This process can limit 
the sensitivity of PCR diagnostic platforms by introducing 
strand brakes into the genomic RNA. However, it has been pre-
viously demonstrated that in comparison with infectious virus, 
PCR detection of gamma-irradiated EBOV differed by a 10–100-
fold dilution that seems to be strain dependent [33]. Therefore, 
the impact of the inactivation process is probably modest, and 
Table 2. Target Detectability for Blood and Semen Samples Over Time
Nominal Copies/mL Target Gene
No. Detected /No. Tested
Blood Samples Semen Samples
Day 1 Day 2 Day 3 Day 1 Day 2 Day 3
1.00 × 106 GP 4/4 2/2 2/2 10/10 10/10 10/10
NP 4/4 2/2 2/2 10/10 10/10 10/10
1.00 × 105 GP 4/4 2/2 2/2 12/12 12/12 6/6
NP 4/4 2/2 2/2 12/12 12/12 6/6
1.00 × 104 GP 3/4 0/2 0/2 5/12 10/12 5/6
NP 4/4 2/2 2/2 12/12 12/12 6/6
1.00 × 103 GP 2/4 0/2 0/2 6/24 7/24 7/22
NP 4/4 2/2 2/2 21/24 20/24 21/22
5.00 × 102 GP 4/8 0/4 0/4 13/24 12/24 6/22
NP 8/8 3/4 4/4 18/24 15/24 13/22
2.50 × 102 GP 5/8 0/4 1/4 5/24 11/24 5/22
NP 4/8 2/4 1/4 12/24 13/24 9/22
Abbreviations: GP, glycoprotein. NP, nucleoprotein.
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the process would produce true limits of assay detection that are 
more conservative than obtained with infectious virus. Finally, 
the Xpert Ebola assay is a qualitative test proved to detect the 
presence of the EBOV virus in the blood, and we have shown 
that this study also performs well for semen. The platform can-
not provide quantitative testing and therefore may have limited 
application to patient care (for informing treatment) or for 
determining infectiousness, and/or transmission.
In conclusion, detection of EBOV in semen with the Cepheid 
Xpert Ebola assay was found to be accurate, with a lower LOD 
of approximately 1000 copies/mL. These results support the 
expanded use of this assay to detect Ebola in semen and blood, 
to guide individual and public health responses during and after 
an outbreak of this virus.
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Figure 2. Xpert Ebola test and instrument stability. Cycle threshold (Ct) values 
are shown for rEbolaGP-NP (positive control). Gray-filled symbols represent gly-
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